Welcome to our dedicated page for Cardlytics SEC filings (Ticker: CDLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Cardlytics, Inc. (NASDAQ: CDLX) SEC filings, including current reports on Form 8-K and other regulatory documents filed with the U.S. Securities and Exchange Commission. Cardlytics operates as a commerce media platform in the advertising services sector, and its filings offer detailed insight into financial performance, governance, and material corporate events.
Recent Form 8-K filings from Cardlytics document a range of topics. Some filings furnish earnings press releases that present quarterly results, including GAAP and non-GAAP measures such as Billings, Adjusted Contribution, Adjusted EBITDA, Adjusted Net Loss, and Free Cash Flow. These filings also describe key operating metrics like monthly qualified users (MQUs) and adjusted contribution per user (ACPU), along with management’s discussion of trends and performance.
Other 8-K filings report material corporate actions such as workforce reduction plans under cost-reduction initiatives, amendments to significant agreements with partners, and changes to executive compensation and severance arrangements. Cardlytics has also filed 8-Ks describing the appointment of a Chief Financial Officer and related equity awards and severance protections, providing detail on compensation terms and vesting conditions.
Through these filings, investors can review how Cardlytics manages its capital structure, including disclosures about convertible senior notes, credit facilities, and repayment of debt. The company’s filings also confirm that its common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the symbol CDLX.
On Stock Titan, users can access Cardlytics’ SEC filings as they are made available from EDGAR, along with AI-powered summaries that help explain the content and implications of complex documents. These tools can assist in understanding Cardlytics’ earnings reports, non-GAAP metrics, insider and executive-related disclosures, and other regulatory information without reading every line of each filing.
Cardlytics, Inc. (CDLX) filed a Form 4 showing that Chief Executive Officer and Director Amit Gupta received sizeable equity grants on 23 June 2025. The award package consists of 1,000,000 Restricted Stock Units (RSUs) and 300,000 Performance Stock Units (PSUs), each convertible into one share of common stock at no cost.
RSU vesting: 50 % of the RSUs vest on 23 June 2026; the remaining 50 % vest quarterly over the following year, ending 23 June 2027, subject to continued employment. PSU vesting: shares vest in stated proportions once specific share-price hurdles are achieved, also contingent on Gupta’s continued service.
The grants increase Gupta’s directly held derivative securities to 1.3 million units. No open-market purchases, sales, or option exercises were reported, and no non-derivative holdings were disclosed in this filing.
While the awards create potential dilution, they combine time-based and performance-based components, linking executive compensation to long-term share price appreciation and retention objectives.
Cardlytics, Inc. (NASDAQ: CDLX) filed an 8-K disclosing revised employment terms for Chief Executive Officer Amit Gupta. On 23 June 2025 the Board approved an Amended & Restated Offer Letter that immediately granted Mr. Gupta 1,000,000 time-based RSUs and 200,000 performance-based PSUs under the 2025 Equity Incentive Plan. The RSUs vest 50 % one year after the grant date and quarterly thereafter through year two. The PSUs vest over a three-year period beginning 1 April 2025, contingent on achieving predetermined share-price targets, with no vesting before 1 April 2026. If Gupta departs before 16 August 2025, any vested RSU value must be repaid in cash.
The company also committed to issue, on or before 31 May 2026, additional equity awards valued at up to $5 million (maximum 1.2 million shares). If the full amount is granted, 1.0 million would be RSUs and 0.2 million PSUs; final terms will be set by the Board or Compensation Committee.
An Amended & Restated Severance Agreement entitles Gupta to 18 months of base salary and medical coverage upon termination without Cause or resignation for Good Reason. Should such termination occur within three months before—or one year after—a Change in Control, all unvested equity will accelerate and fully vest. Other severance terms are unchanged from the prior agreement.
The package strengthens leadership retention and aligns incentives with share-price performance, but authorizes issuance of up to 2.2 million additional shares, implying potential dilution for existing shareholders and increased severance liabilities.